At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.
Phase 2 study is now enrolling.
Castration-resistant prostate cancer (CRPC)